

Certificate Of Mailing Under 37 C.F.R. § 1.10

Express Mailing No. EV 019 435 260 US

Date of Deposit: November 27, 2002

RECEIVED
DEC 03 2002
TECH CENTER 15012900


I hereby certify that the following documents:

1. Supplemental Information Disclosure Statement (in duplicate);
2. PTO-1449 Form (duplicate);
3. Cited reference A2; and
4. this return postcard receipt.


are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington D.C. 20231

Karen DiRocco

(type or printed name of person mailing document(s))


(signature of person mailing document(s))

11-29-02



Express Mail Label No.: E 019 435 260 US
Date of Deposit: November 27, 2002

Attorney Docket No. VPI/00-130-188

#31
12/17/02
REC 03 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Bebbington et al.
ASSIGNEE: Vertex Pharmaceuticals Incorporated
SERIAL NUMBER: 10/026,966 ✓ EXAMINER: Not Yet Assigned
FILING DATE: December 19, 2001 ✓ ART UNIT: 1616
FOR: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS ✓

November 27, 2002
Cambridge, Massachusetts

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

APPLICANTS: Bebbington et al.
U.S.S.N.: 10/026,966

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/00-130-06 US.

Respectfully submitted,



Andrea L. C. Robidoux

Reg. No. 47,902

Agent for Applicant

c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6731
Fax: (617) 444-6483